FDA Holds Public Hearing on Psychedelic Drug Development
核心洞察
The US FDA held a public hearing to gather feedback on the therapeutic use of psychedelic drugs for serious mental illnesses.
The hearing follows an April order directing the FDA to qualify psychedelic programs for its priority-voucher pathway and coordinate with the DEA and VA.
The FDA has since issued priority vouchers for psilocybin in treatment-resistant depression (搜索), psilocybin in major depressive disorder (搜索) and methylone in PTSD.
The US FDA convened a public hearing to collect feedback on the potential therapeutic use of psychedelic drugs, part of a months-long push by the Trump administration to accelerate development of treatments for serious mental illnesses. The effort began in April, when an executive order directed the FDA to focus on qualifying psychedelic drug programs for its priority-voucher program, work with the Drug Enforcement Administration (搜索) on a pathway for some patients to obtain investigational treatments, and increase collaboration with the Department of Veterans Affairs.
Since then, the agency has issued priority vouchers to three companies developing psychedelic-based treatments: one for psilocybin in treatment-resistant depression (搜索), one for psilocybin in major depressive disorder (搜索) and one for methylone in post-traumatic stress disorder (搜索). The hearing addressed provider training and credentials, patient screening and monitoring, access and reimbursement, clinic capacity and collection of long-term safety data. The FDA said it was not seeking views on individual drug applications, controlled-substance scheduling or legalization of psychedelics.
Doctors, veterans, pharmacists and therapists urged the regulator to set clear safety and access standards, with experts saying approved treatments must include trained staff in the room during sessions plus proper screening, follow-up care and community support. Days before the hearing, senior FDA officials including Michael Davis, head of the Center for Drug Evaluation and Research, published a framework in the New England Journal of Medicine for developing and approving psychedelic drugs. The American Psychiatric Association said the FDA's determination of safety and effectiveness must remain the foundation for any future clinical use, while Jefferies analysts said the framework suggested willingness to consider flexible trial designs to address challenges such as functional unblinding.